Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Clara Loveman"'
Autor:
Dmitry Gultyaev, Johanna Lister, Clara Loveman, Marcus J. Drake, Nick Freemantle, Kristin Khalaf, S Stanisic
Publikováno v:
Freemantle, N, Khalaf, K, Loveman, C, Stanisic, S, Gultyaev, D, Lister, J & Drake, M 2016, ' OnabotulinumtoxinA in the treatment of overactive bladder : a cost-effectiveness analysis versus best supportive care in England and Wales ', European Journal of Health Economics, vol. 17, no. 7, pp. 911-921 . https://doi.org/10.1007/s10198-015-0737-2
The cost-effectiveness of onabotulinumtoxinA (BOTOX(®)) 100 U + best supportive care (BSC) was compared with BSC alone in the management of idiopathic overactive bladder in adult patients who are not adequately managed with anticholinergics. BSC inc
Autor:
Quanhong Ni, Rachael McCool, David A. Ginsberg, Julie Glanville, Mick Arber, Nick Freemantle, Kelly Fleetwood, Clara Loveman, Kristin Khalaf
Publikováno v:
BMJ Open
Context OnabotulinumtoxinA and mirabegron have recently gained marketing authorisation to treat symptoms of overactive bladder (OAB). Objective To evaluate the relative efficacy of mirabegron and onabotulinumtoxinA in patients with idiopathic OAB. De
Autor:
Rizwan Hamid, Clara Loveman, Jim Millen, Denise Globe, Catherine Corbell, Danielle Colayco, Sanja Stanisic, Dmitry Gultyaev
Publikováno v:
Pharmacoeconomics
Objectives To evaluate the cost effectiveness of onabotulinumtoxinA (BOTOX®, 200 units [200 U]) for the management of urinary incontinence (UI) in adults with neurogenic detrusor overactivity (NDO) due to subcervical spinal cord injury or multiple s